Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioMarin Deal For La Jolla’s Riquent Rights Comes In Nick Of Time

This article was originally published in The Pink Sheet Daily

Executive Summary

BioMarin could get 50 percent of revenues for very little upfront.

You may also be interested in...



Riquent Trial Fails; Is This La Jolla’s Last Gasp?

Data monitoring board says continuing ASPEN trial is “futile” after first interim look at BioMarin-licensed Riquent trial for treatment of lupus nephritis.

Riquent Trial Fails; Is This La Jolla’s Last Gasp?

Data monitoring board says continuing ASPEN trial is “futile” after first interim look at BioMarin-licensed Riquent trial for treatment of lupus nephritis.

BioMarin Saves Day For La Jolla's Riquent, But All Hangs On Pivotal Trial

With new financing in hand courtesy of BioMarin, La Jolla now hopes to complete its pivotal ASPEN trial for Riquent (abetimus) in lupus nephritis and launch in the U.S. in late 2010

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel